PDSBHealthcare · BiotechnologyPDSB Stock Forecast: PDS Biotechnology Corp. Price Predictions for 2026-2027
The 3 Wall Street analysts covering PDS Biotechnology Corp. hold a median 12-month price target of $4.5 — +483.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 8 Aug 2026 — in the upper half.
PDSB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores PDS Biotechnology Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (27): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own PDS Biotechnology Corp. — and when they’d sell — is the membership.
PDSB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PDSB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +483.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 25 Nov 2025 | B. Riley Securities | Maintains | Buy | — |
| 13 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2024 | B. Riley Securities | Maintains | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2024 | Alliance Global Partners | Maintains | Buy | — |
| 1 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 June 2024 | B. Riley Securities | Maintains | Buy | — |
| 12 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PDSB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
PDS Biotechnology Corp. (PDSB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.0×
- Price / sales
- —
- Price / book
- 11.1×
- EV / EBITDA
- −1.3×
Cheaper than 82% of US stocks
Cheaper than 9% of US stocks
Cheaper than 69% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 33% of US stocks
Higher than 30% of US stocks
- Return on equity
- −254.1%
- Return on assets
- −50.5%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PDSB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PDSB appears on the weeks it earns a place.
Frequently asked questions about PDSB stock
What is the PDSB stock price forecast for 2026-2027?
The 3 Wall Street analysts covering PDS Biotechnology Corp. have a median 12-month price target of $4.5, with estimates ranging from $3 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PDSB stock a buy right now?
Of the 3 analysts covering PDS Biotechnology Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PDS Biotechnology Corp. 59 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PDSB?
As at 8 Aug 2026, PDS Biotechnology Corp. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).
Will PDSB stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +483.7% from the last close, and Ticker Nerd's factor model ranks PDS Biotechnology Corp. 59 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PDSB stock forecast for 2030?
No analyst covering PDS Biotechnology Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PDSB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $15 over the next 12 months.
How has PDSB stock performed over the past year?
PDS Biotechnology Corp. returned -31.2% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does PDS Biotechnology Corp. do?
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. The primary function of PDS Biotechnology is to harness the power of the immune system to eradicate cancer cells, leveraging its proprietary Versamune platform technology.
About PDS Biotechnology Corp.
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. The primary function of PDS Biotechnology is to harness the power of the immune system to eradicate cancer cells, leveraging its proprietary Versamune platform technology. This innovative approach aims to enhance the delivery and presentation of antigens to the immune system, thereby stimulating a potent and targeted immune response against tumors. PDS Biotechnology is deeply integrated into the healthcare and biotechnology sectors, particularly impacting the development of therapies for various types of cancer, including head and neck, anal, and cervical cancers, as well as other oncology indications. As a significant player in the field of immuno-oncology, PDS Biotechnology contributes to advancing cancer treatment options by focusing on safer and more efficient therapeutic vaccines and combines cutting-edge science with clinical applications to potentially improve patient outcomes. Its commitment to innovation positions the company as a critical driver of progress in next-generation cancer therapies within the financial market.
CEO Dr. Frank K. Bedu-Addo Ph.D. · 21 employees · United States · https://www.pdsbiotech.com